Does Lexapro Affect CYP2D6?
Yes, Lexapro (escitalopram) has a modest inhibitory effect on CYP2D6, though it is primarily metabolized by CYP2C19 and CYP3A4, not CYP2D6. 1
Escitalopram's Relationship with CYP2D6
As a Substrate
Escitalopram is not significantly metabolized by CYP2D6. The primary enzymes responsible for escitalopram metabolism are CYP3A4 and CYP2C19 1. However, CYP2D6 does play a role in metabolizing the active metabolite S-demethylcitalopram (S-DCT) 2.
As an Inhibitor
Escitalopram acts as a weak-to-modest inhibitor of CYP2D6 1. The FDA label explicitly states that "results from drug interaction studies suggest that escitalopram, at a dose of 20 mg, has no 3A4 inhibitory effect and a modest 2D6 inhibitory effect" 1.
Clinical Significance
Effect on CYP2D6 Substrates
When escitalopram is co-administered with drugs metabolized by CYP2D6, clinically relevant interactions can occur:
Metoprolol: Administration of escitalopram 20 mg/day for 21 days resulted in a 50% increase in Cmax and 82% increase in AUC of metoprolol 1. This is clinically significant as increased metoprolol levels are associated with decreased cardioselectivity.
Desipramine: Co-administration of escitalopram 20 mg/day for 21 days with desipramine (a CYP2D6 substrate) resulted in a 40% increase in Cmax and 100% increase in AUC of desipramine 1.
Comparative Inhibitory Potency
Among SSRIs, escitalopram is a relatively weak CYP2D6 inhibitor 3:
- Potent inhibitors: Fluoxetine, paroxetine
- Moderate inhibitors: Duloxetine, bupropion
- Weak inhibitors: Escitalopram, citalopram, sertraline (at low doses), venlafaxine
A direct comparison study showed that duloxetine produced a 180% increase in metoprolol AUC, escitalopram 89%, and sertraline 48-67% 4. The differences between escitalopram and sertraline were not statistically significant.
Clinical Recommendations
Exercise caution when co-administering escitalopram with drugs metabolized by CYP2D6, particularly those with narrow therapeutic indices 1. This includes:
- Beta-blockers (especially metoprolol): Monitor for excessive beta-blockade (bradycardia, hypotension)
- Tricyclic antidepressants: Consider dose reduction if combining
- Antiarrhythmics: Monitor cardiac function closely
- Certain antipsychotics: Watch for increased side effects
Practical Approach
- For patients on metoprolol or other CYP2D6 substrates, consider starting with lower doses when adding escitalopram
- Monitor for signs of increased drug effect (e.g., excessive beta-blockade with metoprolol)
- If significant interactions occur, consider switching to an SSRI with even less CYP2D6 inhibition (though options are limited) or adjusting the dose of the CYP2D6 substrate
Important Caveat
While escitalopram does inhibit CYP2D6, its own metabolism is not significantly affected by CYP2D6 genetic polymorphisms 5. Recent evidence shows that CYP2D6 phenotype has minimal impact on escitalopram pharmacokinetics compared to CYP2C19, though combined CYP2C19/CYP2D6 poor metabolizer status can result in modestly higher escitalopram levels (24-31% increase) 5.